Phathom Pharmaceuticals (PHAT) News Today $4.29 -0.07 (-1.61%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Position Lowered by Gilder Gagnon Howe & Co. LLCGilder Gagnon Howe & Co. LLC trimmed its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 97.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,610 shares of the company's stock after selling 1,581,273 sharesApril 30 at 6:13 AM | marketbeat.com455,837 Shares in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Purchased by Raymond James Financial Inc.Raymond James Financial Inc. purchased a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 455,837 shares of the company's stock, valApril 29 at 3:49 AM | marketbeat.comPhathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual MeetingApril 28 at 7:59 AM | globenewswire.comDecheng Capital LLC Trims Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Decheng Capital LLC cut its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 44.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 694,254 shares of the company'sApril 28 at 7:18 AM | marketbeat.comPropel Bio Management LLC Buys 120,000 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Propel Bio Management LLC lifted its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 13.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 989,927 shares of the company's stock after buying an aApril 28 at 6:54 AM | marketbeat.comPhathom Pharmaceuticals (PHAT) to Release Earnings on ThursdayPhathom Pharmaceuticals (NASDAQ:PHAT) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-phathom-pharmaceuticals-inc-stock/)April 27 at 1:43 AM | marketbeat.comGeode Capital Management LLC Acquires 155,577 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Geode Capital Management LLC boosted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 18.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,018,495 shares of the company's stock after puApril 26, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Monday.April 23, 2025 | marketbeat.comPhathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025April 23, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Earns "Buy" Rating from Needham & Company LLCApril 22, 2025 | americanbankingnews.comThe Goldman Sachs Group Lowers Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $10.00The Goldman Sachs Group lowered their price objective on shares of Phathom Pharmaceuticals from $12.00 to $10.00 and set a "neutral" rating on the stock in a research report on Thursday.April 20, 2025 | marketbeat.comInvesco Ltd. Has $29.81 Million Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Invesco Ltd. decreased its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 10.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,671,386 shares of the company's stock after selling 425,376 shares duringApril 20, 2025 | marketbeat.comWasatch Advisors LP Purchases 1,311,986 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Wasatch Advisors LP increased its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 531.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,558,928 shares of the company's stock after purchasing an adApril 19, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years agoApril 18, 2025 | finance.yahoo.comVanguard Group Inc. Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Vanguard Group Inc. increased its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,779,561 shares of thApril 17, 2025 | marketbeat.comPhathom Pharmaceuticals appoints Schroeder to board of directorsApril 16, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Appoints Ted Schroeder to its Board of DirectorsApril 16, 2025 | globenewswire.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Wednesday.April 11, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells $16,734.90 in StockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) CFO Molly Henderson sold 3,678 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $4.55, for a total transaction of $16,734.90. Following the completion of the transaction, the chief financial officer now directly owns 89,868 shares in the company, valued at approximately $408,899.40. This represents a 3.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.April 10, 2025 | marketbeat.comInsider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 3,678 Shares of StockApril 9, 2025 | insidertrades.comTrexquant Investment LP Makes New $3.08 Million Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Trexquant Investment LP acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 378,637 shares of the company's stock, valued at approximately $3,075,000. TrexquanApril 8, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Buy" by BrokeragesPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has been assigned an average recommendation of "Buy" from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have givenApril 6, 2025 | marketbeat.com‘Saturday Night Live’ cast member breaks silence on health issueApril 5, 2025 | msn.comGuggenheim Reiterates "Buy" Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)Guggenheim reiterated a "buy" rating on shares of Phathom Pharmaceuticals in a research report on Wednesday.April 4, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Wednesday.April 4, 2025 | marketbeat.comPhathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade)April 3, 2025 | seekingalpha.comPhathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 3, 2025 | globenewswire.comNeedham Remains a Buy on Phathom Pharmaceuticals (PHAT)April 2, 2025 | markets.businessinsider.comExclusive: How SNL Legend Kenan Thompson’s Disease Gave Him This ‘Light Bulb Moment’ as a Girl DadApril 2, 2025 | msn.comKenan Thompson Reveals How He’ll Know It’s Time to Leave ‘SNL’ After More Than 20 Years (Exclusive)April 2, 2025 | msn.comPhathom Pharmaceuticals appoints Basta as President, CEOApril 2, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Stock Falls on CEO SwitchApril 2, 2025 | marketwatch.comPhathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comPhathom Pharmaceuticals Names Basta President, CEO as Curran ResignsApril 1, 2025 | marketwatch.comPhathom Pharmaceuticals Announces Leadership SuccessionApril 1, 2025 | globenewswire.comPhathom Pharmaceuticals partners with Kenan Thompson for GERD awarenessMarch 31, 2025 | markets.businessinsider.comActor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)March 31, 2025 | globenewswire.comRaymond James Financial Inc. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Raymond James Financial Inc. acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 455,837 shares of the company's sMarch 28, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $2.87 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Charles Schwab Investment Management Inc. raised its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 20.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 353,038 shares of the comMarch 28, 2025 | marketbeat.comSimplify Asset Management Inc. Grows Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Simplify Asset Management Inc. lifted its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 11.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 581,9March 24, 2025 | marketbeat.comPhathom Pharmaceuticals price target lowered to $13 from $17 at JefferiesMarch 20, 2025 | markets.businessinsider.comPhathom Pharmaceuticals director buys $44.2K shares of common stockMarch 17, 2025 | markets.businessinsider.comThe Goldman Sachs Group Issues Pessimistic Forecast for Phathom Pharmaceuticals (NASDAQ:PHAT) Stock PriceThe Goldman Sachs Group cut their price objective on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a "neutral" rating for the company in a research report on Monday.March 11, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Buy" from AnalystsShares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and oMarch 11, 2025 | marketbeat.comPhathom Pharmaceuticals’ Earnings Call: Growth and ChallengesMarch 10, 2025 | tipranks.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comPhathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call TranscriptMarch 9, 2025 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday.March 8, 2025 | marketbeat.comPhathom Pharmaceuticals price target lowered to $12 from $18 at Goldman SachsMarch 7, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Full Year 2024 Earnings: Beats ExpectationsMarch 7, 2025 | uk.finance.yahoo.com Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Media Mentions By Week PHAT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼1.020.85▲Average Medical News Sentiment PHAT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼83▲PHAT Articles Average Week Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Syndax Pharmaceuticals News Adaptive Biotechnologies News Aurinia Pharmaceuticals News 89bio News Wave Life Sciences News Enliven Therapeutics News X4 Pharmaceuticals News Zymeworks News Pharvaris News Spyre Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHAT Stock Free PHAT Stock Alerts